View examples of how we address the unique need of every research question to deliver innovative, multidimensional solutions to convey the value of healthcare innovations. Download our posters from recent conferences.

Virtual ISPOR Europe 2020 PostersLink
Treatment Sequencing in Modeling the Economic Benefits of Psoriasis Therapy- IMPACT of Key AssumptionsDownload
Efficacy and Safety in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – A Systematic Literature Review UpdateDownload
Overall Complete Remission Rate (OCRR) and Complete Remission Rate (CR) Of Standard of Care (SoC) In Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Meta-AnalysisDownload
Real-World Effectiveness in Previously Untreated, Advanced/ Metastatic Renal Cell Carcinoma – A Systematic Literature Review UpdateDownload
Cost-Effectiveness Models and Resource Use/Cost Inputs for Untreated Advanced/Metastatic Renal Cell Carcinoma- A Systematic Literature ReviewDownload
Global Incidence, Prevalence, and Survival in Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Systematic Literature Review (SLR)Download
Clinical Characteristics and Minimal Residual Disease (MRD) Testing Patterns in NEWLY Diagnosed Patients with B-CELL Precursor ACUTE Lymphoblastic Leukemia (ALL) from Italy: A Retrospective
Chart Review
Download
Reported Utilities for Patients with Previously Untreated Advanced/ Metastatic Renal Cell Carcinoma – A Systematic Literature ReviewDownload
Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC)Download
Existing Health Economic Evaluations of Inflammatory Bowel Disease Show Important Methodological Limitations: A Targeted Literature ReviewDownload
Where Are We Headed with Digital Therapeutics? A Systematic Review of the EvidenceDownload
Identifying Appropriate PROXY Diseases for Estimating LONG-TERM Survival and IMPACT on Health-Related Quality of Life of Patients with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D)Download
Estimating the LONG-TERM Effects of Therapy for Patients with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) Using Individual Participant DATADownload
Synthesizing Evidence on Progression-Free Survival and Assessing The Feasibility of Network Meta-Analyses in Previously Untreated Advanced/Metastatic Renal Cell Carcinoma TherapiesDownload
The Impact of Clinical Heterogeneity on Conducting Network MetaAnalyses for Overall Survival in Previously Untreated Intermediate- or Poor-Risk Advanced/Metastatic Renal Cell Carcinoma TherapiesDownload
Synthesizing Evidence on Overall Survival and Assessing the Feasibility of Network Meta-Analyses in Previously Untreated Advanced/Metastatic Renal Cell Carcinoma TherapiesDownload
The Impact of Clinical Heterogeneity on Conducting Network Meta-Analyses for Progression-Free Survival of Previously Untreated Intermediate- or Poor-Risk Advanced/Metastatic Renal Cell Carcinoma TherapiesDownload
Systematic Identification of Potential Treatment Effect Modifiers in First Line Advanced Renal Cell CarcinomaDownload
Stroke and Bleeding Outcomes in Europe and ASIA in Patients with Nonvalvular Atrial Fibrillation Treated with NON-Vitamin K ORAL Anticoagulants (NOACS) in Real-Word Practice Renal Cell Carcinoma TherapiesDownload
Economic and Humanistic Outcomes Associated with Treatment of Recurrent Ormetastatic Cervical Cancer: A Literature ReviewDownload
Budget Impact Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma Who Have Received At Least One Prior Therapy From The Payer Perspective in the United StatesDownload
Patient Reported Outcomes Among Kte-X19 CAR T Treated Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)Download
AMCP Nexus 2020 Virtual Conference PosterLink
Burden of Parkinson’s Disease in a Real-World Sample of Patients with Motor FluctuationsDownload
Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Cost Associated with First-Line Therapies for Elderly Patients with Mantle Cell LymphomaDownload
Real-World Incidence and Management of Adverse Events (AEs) in Patients with Non-Metastatic Castrate-Resistant Prostate Cancer Receiving Apalutamide or EnzalutamideDownload
23rd International AIDS Conference PosterLink
Comparative Efficacy and Safety of a Combination Therapy of Dolutegravir and Lamivudine VS 3-Drug Antiretroviral Regimens in Treatment-Naive HIV-1 Infected Patients at 96 Weeks: A Systematic Review and Network Meta-AnalysisDownload
ISPOR 2020 PostersLink
Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United StatesDownload
Budget Impact Analysis of Introduction of Rituximab Biosimilar in the United States from a Payer PerspectiveDownload
Comparison of Treatment Adherence And Persistence with Edoxaban Versus Apixaban, Dabigatran, Rivaroxaban, and Vitamin K Antagonist in Non-Valvular Atrial Fibrillation Patients in Germany: A Propensity Matched Cohort StudyDownload
Budget Impact Analysis of Introduction of Bevacizumab Biosimilar in the United States from a Payer PerspectiveDownload
Budget Impact Analysis of Introduction of IV Trastuzumab Biosimilar (Trastuzumab-qyyp) from Buyer and Payer Perspectives in FranceDownload
Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Spinal SurgeryDownload
Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Cardiovascular SurgeryDownload
ISPOR Europe SymposiumLink
SURVIVAL MODELLING: TRENDS AND INNOVATIONSDownload
ISPOR HEOR TheaterLink
COMMUNICATING VALUE TO DECISION-MAKERS: WHAT’S YOUR PROGNOSIS?Download
ISPOR Europe 2019 PostersLink
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALYDownload
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAINDownload
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLANDDownload
UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMADownload
STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMADownload
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECEDownload
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCEDownload
USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETYDownload
BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMABDownload
MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALSDownload
COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPEDownload
MAXIMUM LIKELIHOOD ESTIMATION TO QUANTIFY THE IMPACT OF TREATMENT RESPONSE ON SURVIVAL OUTCOMESDownload
BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIADownload
IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OSDownload
AMCP Nexus 2019Link
CHARACTERISTICS, SYSTEMIC TREATMENTS AND OUTCOMES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC LITERATURE REVIEWDownload